title: GHR exon 3 polymorphism: association with type 2 diabetes mellitus and metabolic disorder.
abstract: Growth hormone (GH) signaling via the growth hormone receptor (GHR) forms a major part of the GH-IGF-I axis, which is crucial for controlling metabolism and anabolism. Two common variants of the GHR differ by the presence (full length or GHR(fl)) or absence of exon 3 (exon 3 deleted or GHR(d3)), the function of which is unknown. However, differential response to GH treatment has been observed with carriers of the GHR(d3) variant conferring a greater growth rate. This study investigates these GHR variants in subjects with normal glucose tolerance (NGT) and impaired glucose tolerance (IGT), including Type 2 diabetes mellitus (T2DM). DNA was extracted from blood samples from subjects with NGT (n=158), IGT (n=116) and T2DM (n=194). The T2DM subjects in set 1 (n= 39) were newly diagnosed, whilst those in set 2 (n=155) had a mean duration of 7 years. Set 1 also included NGT and IGT subjects. Genotyping by standard PCR and gel electrophoresis were carried out. A significant difference was observed between T2DM and NGT (p<0.0001) with a significantly lower frequency of GHR(d3) in T2DM (3.6% compared to 17% in NGT). Both sets of T2DM subjects with at least one GHR(d3) allele had significantly higher BMI. In the larger subset of T2DM, GHR(d3) was associated with higher CRP levels as well as age adjusted IGF-I, with a trend of higher C-peptide secretion and impaired lipid levels, indicating a phenotype with metabolic disorder when compared to the GHR(fl/fl) T2DM subjects. In conclusion, homozygosity for the GHR(d3) allele appears to be preventive of T2DM. However, when other factors cause overt T2DM, the GHR(d3) allele confers a phenotype indicative of metabolic disorder. This study supports the hypothesis that the two GHR alleles by their inclusion or exclusion of exon 3 are functionally different.
authors.affiliation: Department of Oncology Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Solna, 171 76 Stockholm, Sweden. rona.strawbridge@ki.se
authors.forename: R J
authors.initials: RJ
authors.lastname: Strawbridge
authors.forename: L
authors.initials: L
authors.lastname: Kärvestedt
authors.forename: C
authors.initials: C
authors.lastname: Li
authors.forename: S
authors.initials: S
authors.lastname: Efendic
authors.forename: C G
authors.initials: CG
authors.lastname: Ostenson
authors.forename: H F
authors.initials: HF
authors.lastname: Gu
authors.forename: K
authors.initials: K
authors.lastname: Brismar
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D002352:Carrier Proteins / Q000235:genetics*; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics*; D005091:Exons; D005260:Female; D018149:Glucose Intolerance / Q000235:genetics; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D008659:Metabolic Diseases / Q000235:genetics*; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011384:Proinsulin / Q000097:blood; D012016:Reference Values
chemical_list: D001786:Blood Glucose; D002352:Carrier Proteins; D007328:Insulin; D011384:Proinsulin; C051815:somatotropin-binding protein